Orchestra BioMed went public via merger with Health Sciences Acquisitions II in a $158m deal.

Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, went public via merger with Health Sciences Acquisitions II, a blank check company, in a $158m deal. “Orchestra BioMed is pioneering an innovative business model designed to leverage partnerships with global medical device leaders like Medtronic and Terumo to accelerate the development and commercialization of high-impact device therapies like BackBeat CNT and Virtue SAB. With a strong balance sheet, a top-flight shareholder base, and world-class strategic collaborators, this transaction puts us in an excellent position to address the unmet needs of patients and physicians while seeking to generate differentiated growth for our stockholders. We have several important milestones ahead of us, including the expected initiation of pivotal trials this year for both BackBeat CNT and Virtue SAB. These innovative technologies are supported by strong proof-of-concept clinical data, fueling our excitement for Orchestra BioMed as it enters the public markets and the next phase of its corporate evolution.” David Hochman, Orchestra BioMed Chairman and CEO.